Compare Abeona Therapeutics Inc (ABEO) vs iShares Self-Driving EV and Tech (IDRV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares Self-Driving EV and Tech — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while iShares Self-Driving EV and Tech trades at $37.18. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares Self-Driving EV and Tech nearer its low. Which is the better fit depends on your goals.
| ABEO | IDRV | |
|---|---|---|
Market Cap | $421.19M | — |
Sector | Health | Sector/Thematic |
52-Week High | $7.45 | $45.48 |
52-Week Low | $4.17 | $34.49 |
Enterprise Value | $276.10M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.
Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.
IDRV trades at $37.24, down 0.35% on the day, with a bullish technical signal driven by moving averages. The stock is positioned near its pivot point of $37, with key resistance at $38 and support at $36. Recent news highlights strong global EV sales growth and China's ambitious 2030 fleet target, supporting the thematic focus of the fund.
The outlook for IDRV is supported by positive industry trends in electric vehicles, though the absence of key valuation and profitability ratios limits fundamental assessment. Risks include competitive pressures and regulatory changes, while analyst sentiment is mixed with a slight bullish bias. The stock's performance remains tied to broader EV market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares Self-Driving EV and Tech
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →
